Malta - English - Medicines Authority

astrazeneca uk limited - chlortalidone; atenolol - film-coated tablet - chlortalidone 25 mg; atenolol 100 mg - beta blocking agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution - 0.5% - timolol (timolol maleate) 0.5% - beta-adrenergic agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution - 0.25% - timolol (timolol maleate) 0.25% - beta-adrenergic agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution - 0.25% - timolol (timolol maleate) 0.25% - beta-adrenergic agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution - 0.5% - timolol (timolol maleate) 0.5% - beta-adrenergic agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution (extended release) - 0.25% - timolol (timolol maleate) 0.25% - beta-adrenergic agents

Canada - English - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution (extended release) - 0.5% - timolol (timolol maleate) 0.5% - beta-adrenergic agents

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - glycerin 0.525 ml in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - morella cerifera pollen (unii: lc8mev9s89) (morella cerifera pollen - unii:lc8mev9s89) - morella cerifera pollen 0.05 g in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - english sole (unii: 00cr8124as) (english sole - unii:00cr8124as) - english sole 0.05 g in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.